Kartik Konduri, MD
Medical Oncology · Dallas, TXNPI 1417995499
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AstraZeneca at 25.2% of the total. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $1195.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$48K
- EMD Serono, Inc.$21K
- E.r. Squibb & Sons, L.L.C.$20K
- Amgen$17K
- Jazz Pharmaceuticals Inc.$11K
- Johnson & Johnson$11K
- plus $63K from 21 others
Across 451 payments — averaging $6910.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$602K
- Mirati Therapeutics, Inc.$577K
- Genentech, Inc.$437K
- Merck$328K
- Puma Biotechnology, Inc.$198K
- AstraZeneca$185K
- plus $789K from 18 others
What the payments were for
- Consulting fees$102,05953%
- Speaking & faculty fees$80,23442%
- Travel & lodging$6,9604%
- Food & beverage$1,9491%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $48,236 |
| EMD Serono, Inc. | 5 | $20,868 |
| E.r. Squibb & Sons, L.L.C. | 15 | $20,012 |
| Amgen | 17 | $17,467 |
| Jazz Pharmaceuticals Inc. | 7 | $10,904 |
| Johnson & Johnson | 7 | $10,537 |
| Mirati Therapeutics, Inc. | 12 | $8,414 |
| Daiichi Sankyo Inc. | 8 | $7,498 |
| AbbVie | 8 | $6,538 |
| Novocure Inc. | 7 | $5,722 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $5,470 |
| Regeneron | 6 | $5,373 |
| Boehringer Ingelheim | 1 | $3,870 |
| Pfizer | 2 | $3,600 |
| Regeneron Healthcare Solutions, Inc. | 3 | $2,801 |
| Bayer | 1 | $2,750 |
| Lilly USA, LLC | 1 | $2,400 |
| Blueprint Medicines Corporation | 1 | $2,240 |
| Eli Lilly | 1 | $1,875 |
| Janssen Scientific Affairs, LLC | 2 | $1,828 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,319 |
| Boehringer Ingelheim International GmbH | 1 | $860 |
| G1 Therapeutics, Inc. | 2 | $634 |
| Genentech USA, Inc. | 1 | $40 |
| Novartis | 2 | $28 |
| Merck | 1 | $22 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$191,317 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 84 | $1,393,850 |
| TabrectaCapmatinib Hydrochloride | 28 | $320,725 |
| LumakrasSotorasib | 13 | $282,744 |
| MekinistTrametinib Dimethyl Sulfoxide | 22 | $276,727 |
| TafinlarDabrafenib Mesylate | 18 | $240,531 |
| AlecensaAlectinib Hcl | 14 | $229,620 |
| Everolimus | 12 | $101,244 |
| EliquisApixaban | 36 | $20,145 |
| Dexamethasone | 81 | $1,084 |
| Ondansetron Hcl | 52 | $366 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $170 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $164 |
| Doxycycline Hyclate | 13 | $123 |
| ValacyclovirValacyclovir Hcl | 12 | $96 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $48,236 | $1,393,85084 claims |
| NovartisTabrecta, Mekinist, Tafinlar | $28 | $837,98368 claims |
| AmgenLumakras | $17,467 | $282,74413 claims |
| Genentech USA, Inc.Alecensa | $40 | $229,62014 claims |
| PfizerEliquis | $3,600 | $20,14536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.